View Item 

Show simple item record

Sociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal Study
dc.contributor.authorYelin, Edwarden_US
dc.contributor.authorTonner, Chrisen_US
dc.contributor.authorKim, Seoyoung C.en_US
dc.contributor.authorKatz, Jeffrey N.en_US
dc.contributor.authorAyanian, John Z.en_US
dc.contributor.authorBrookhart, M. Alanen_US
dc.contributor.authorSolomon, Daniel H.en_US
dc.date.accessioned2014-07-03T14:41:28Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-07-03T14:41:28Z
dc.date.issued2014-07en_US
dc.identifier.citationYelin, Edward; Tonner, Chris; Kim, Seoyoung C.; Katz, Jeffrey N.; Ayanian, John Z.; Brookhart, M. Alan; Solomon, Daniel H. (2014). "Sociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal Study." Arthritis Care & Research 66(7): 980-989.en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/107532
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherDartmouth Medical Schoolen_US
dc.titleSociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal Studyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/107532/1/acr22244.pdf
dc.identifier.doi10.1002/acr.22244en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceCenter for the Evaluative Clinical Sciences at Dartmouth Medical School. Dartmouth Atlas of Health Care. Lebanon (NH): Dartmouth Medical School; 2004.en_US
dc.identifier.citedreferenceSchmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007; 57: 928 – 34.en_US
dc.identifier.citedreferenceSchmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease‐modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011; 305: 480 – 6.en_US
dc.identifier.citedreferenceSolomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN. Use of disease‐modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken) 2012; 64: 184 – 9.en_US
dc.identifier.citedreferenceTavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazovskis J, et al. Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. J Rheumatol 2011; 38: 2342 – 5.en_US
dc.identifier.citedreferenceTavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazovskis J, et al. Time to disease‐modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. J Rheumatol 2012; 39: 2088 – 97.en_US
dc.identifier.citedreferenceChu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB. Racial/ethnic differences in the use of biologic disease‐modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013; 65: 299 – 303.en_US
dc.identifier.citedreferencePutrik P, Ramiro S, Kvien T, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 198 – 206.en_US
dc.identifier.citedreferenceKawachi I, Subramanian SV, Almeida‐Filho N. A glossary for health inequalities. J Epidemiol Community Health 2002; 56: 647 – 52.en_US
dc.identifier.citedreferenceBraveman PA. Monitoring equity in health and healthcare: a conceptual framework. J Health Popul Nutr 2003; 21: 181 – 92.en_US
dc.identifier.citedreferenceYelin E, Henke C, Kramer J, Nevitt MC, Shearn M, Epstein WV. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee‐for‐service practices. N Engl J Med 1985; 312: 962 – 7.en_US
dc.identifier.citedreferenceYelin E, Criswell L, Feigenbaum P. Health care utilization and outcomes among persons with rheumatoid arthritis in fee‐for‐service and prepaid group practices. J Am Med Assoc 1996; 276: 1048 – 53.en_US
dc.identifier.citedreferenceKatz PP, Morris A, Yelin EH. Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 763 – 9.en_US
dc.identifier.citedreferenceU.S. Bureau of the Census. Design and methodology: American Community Survey. Washington, DC: U.S. Government Printing Office; 2009.en_US
dc.identifier.citedreferenceVenkateshan SP, Sidhu S, Malhotra S, Pandhi P. Efficacy of biologicals in the treatment of rheumatoid arthritis: a meta‐analysis. Pharmacology 2009; 83: 1 – 9.en_US
dc.identifier.citedreferenceKuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta‐ analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298 – 304.en_US
dc.identifier.citedreferenceCook NL, Hicks LS, O'Malley AJ, Keegan T, Guadagnoli E, Landon BE. Access to specialty care and medical services in community health centers. Health Aff (Millwood) 2007; 26: 1459 – 68.en_US
dc.identifier.citedreferenceMehrotra A, Forrest CB, Lin CY. Dropping the baton: specialty referrals in the United States. Milbank Q 2011; 89: 39 – 68.en_US
dc.identifier.citedreferenceGoldman D, Joyce G, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood) 2006; 25: 1319 – 31.en_US
dc.identifier.citedreferenceBarton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient‐physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 857 – 64.en_US
dc.identifier.citedreferenceFraenkel L, Peters E, Charpentier P, Olsen B, Errante L, Schoen RT, et al. Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 977 – 85.en_US
dc.identifier.citedreferenceSaag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762 – 84.en_US
dc.identifier.citedreferenceSingh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625 – 39.en_US
dc.identifier.citedreferenceLaCaille D, Anis A, Guh D, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005; 53: 241 – 8.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr22244.pdf
Size:
201.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.